A Prospective Cohort Study to Define the Clinical and Pathological Features of Lung Cancers Harboring HER2 Gene Aberrations (The HER2-CS Study) and a Phase II Study of Trastuzumab Emtansine (Recombinant) in Patients With HER2-positive Non-Small Cell Lung Cancer Who Recurred, Progressed After Standard Chemotherapy, or Were Primarily Refractory to Standard Chemotherapy

Okayama Igakkai Zasshi (Journal of Okayama Medical Association)

doi 10.4044/joma.127.127